BIOCARTIS GROUP NV |
Real-time
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.29 EUR | +1.05% |
|
-.--% | -.--% |
Presenter SpeechRenate Degrave (Executives)Good day, and welcome. Following today's presentati...
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
Subscribe
Biocartis Group NV specializes in the development of molecular diagnostic systems. Especially for the treatment of cancers and infectious diseases, the products ensure the analysis of biomolecules associated with risk factors, early detection, treatment selection and monitoring of disease. The group has the Idylla system to deliver results within a period of between 35 to 150 minutes.
Net sales by source of income are mainly distributed between products sales (78.3%) and sale of collaboration services (19.3%; especially research and development services).
Calendar
2024-09-04
- Q2 2024 Earnings Release (Projected)
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -.--% | 29.4M | |
| +73.37% | 12.4B | |
| -18.59% | 7.94B | |
| -0.90% | 6.17B | |
| +15.76% | 5.55B | |
| -4.32% | 5.35B | |
| +40.80% | 5.03B | |
| -17.73% | 4.07B | |
| -29.79% | 2.65B | |
| +7.56% | 1.93B |
- Stock Market
- Equities
- BCART Stock
- News Biocartis Group NV
- Transcript : Biocartis Group NV, 2017 Earnings Call, Mar 01, 2018